PLoS ONE (Jan 2015)

Familial risks and estrogen receptor-positive breast cancer in Hong Kong Chinese women.

  • Lap Ah Tse,
  • Mengjie Li,
  • Wing-cheong Chan,
  • Chi-hei Kwok,
  • Siu-lan Leung,
  • Cherry Wu,
  • Ignatius Tak-sun Yu,
  • Wai-cho Yu,
  • Xiangqian Lao,
  • Xiaorong Wang,
  • Carmen Ka-man Wong,
  • Priscilla Ming-yi Lee,
  • Feng Wang,
  • Xiaohong Rose Yang

DOI
https://doi.org/10.1371/journal.pone.0120741
Journal volume & issue
Vol. 10, no. 3
p. e0120741

Abstract

Read online

The role of family history to the risk of breast cancer was analyzed by incorporating menopausal status in Hong Kong Chinese women, with a particular respect to the estrogen receptor-positive (ER+) type.Seven hundred and forty seven breast cancer incident cases and 781 hospital controls who had completed information on family cancer history in first-degree relatives (nature father, mother, and siblings) were recruited. Odds ratio for breast cancer were calculated by unconditional multiple logistic regression, stratified by menopausal status (a surrogate of endogenous female sex hormone level and age) and type of relative affected with the disease. Further subgroup analysis by tumor type according to ER status was investigated.Altogether 52 (6.96%) breast cancer cases and 23 (2.95%) controls was found that the patients' one or more first-degree relatives had a history of breast cancer, showing an adjusted odds ratio (OR) of 2.41 (95%CI: 1.45-4.02). An excess risk of breast cancer was restricted to the ER+ tumor (OR = 2.43, 95% CI: 1.38-4.28), with a relatively higher risk associated with an affected mother (OR = 3.97, 95%CI: 1.46-10.79) than an affected sister (OR = 2.06, 95%CI: 1.07-3.97), while the relative risk was more prominent in the subgroup of pre-menopausal women. Compared with the breast cancer overall, the familial risks to the ER+ tumor increased progressively with the number of affected first-degree relatives.This study provides new insights on a relationship between family breast cancer history, menopausal status, and the ER+ breast cancer. A separate risk prediction model for ER+ tumor in Asian population is desired.